# Tavo Biotherapeutics jobs and careers

> 0 open roles at Tavo Biotherapeutics as of October 23, 2026. Source: https://www.thejobsmap.com/company/tavo-biotherapeutics

Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology. TAV-001 engages two novel targets that represent fundamental mechanisms underlying the pathology of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown signals of neuroprotection as well as substantial reduction in intraocular pressure, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic retinopathy, diabetic macular edema, and both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Employees | 11 to 50 |
| Website | https://tavobio.com |

## Leadership

- Gary Berman, CEO

## Common questions

### Is Tavo Biotherapeutics hiring right now?

Tavo Biotherapeutics has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on Tavo Biotherapeutics's careers site.

### Who leads Tavo Biotherapeutics?

Gary Berman, CEO, is at the top of Tavo Biotherapeutics's org chart.

### How do I apply for a job at Tavo Biotherapeutics?

Pick a role on Tavo Biotherapeutics's TheJobsMap page and select Apply. Every listing links to the original posting on Tavo Biotherapeutics's own careers site, so you apply directly with the employer.